WO2023275149A1 - Composition comprising vitamin k, vitamin d - Google Patents
Composition comprising vitamin k, vitamin d Download PDFInfo
- Publication number
- WO2023275149A1 WO2023275149A1 PCT/EP2022/067908 EP2022067908W WO2023275149A1 WO 2023275149 A1 WO2023275149 A1 WO 2023275149A1 EP 2022067908 W EP2022067908 W EP 2022067908W WO 2023275149 A1 WO2023275149 A1 WO 2023275149A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- composition
- prodrug
- compositions
- immune
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 126
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 39
- 229940046010 vitamin k Drugs 0.000 title description 7
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims abstract description 80
- 235000019143 vitamin K2 Nutrition 0.000 claims abstract description 66
- 239000011728 vitamin K2 Substances 0.000 claims abstract description 66
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims abstract description 62
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 43
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 38
- 239000011710 vitamin D Substances 0.000 claims abstract description 38
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 38
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 38
- 239000000651 prodrug Substances 0.000 claims abstract description 34
- 229940002612 prodrug Drugs 0.000 claims abstract description 34
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 23
- 239000011700 menaquinone-7 Substances 0.000 claims description 22
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 claims description 21
- 230000036541 health Effects 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 18
- 239000002417 nutraceutical Substances 0.000 claims description 16
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 235000005282 vitamin D3 Nutrition 0.000 claims description 7
- 239000011647 vitamin D3 Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 229940021056 vitamin d3 Drugs 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 108700012920 TNF Proteins 0.000 claims description 3
- 230000008482 dysregulation Effects 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006052 feed supplement Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 6
- 229930003448 Vitamin K Natural products 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 235000019175 phylloquinone Nutrition 0.000 description 6
- 239000011772 phylloquinone Substances 0.000 description 6
- 229960001898 phytomenadione Drugs 0.000 description 6
- 235000019168 vitamin K Nutrition 0.000 description 6
- 239000011712 vitamin K Substances 0.000 description 6
- 208000020084 Bone disease Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000003505 terpenes Chemical group 0.000 description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- -1 isoprenyl Chemical group 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000011575 calcium Chemical class 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- FRASJONUBLZVQX-UHFFFAOYSA-N naphthoquinone group Chemical group C1(C=CC(C2=CC=CC=C12)=O)=O FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 229940041603 vitamin k 3 Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 125000000695 menaquinone group Chemical group 0.000 description 2
- 239000011676 menaquinone-4 Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 229930182559 Natural dye Natural products 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical class [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000207449 Prunus puddum Species 0.000 description 1
- 235000009226 Prunus puddum Nutrition 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000004988 autoimmune vasculitis Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000010949 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011574 phosphorus Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001550 polyprenyl Polymers 0.000 description 1
- 125000001185 polyprenyl group Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000979 synthetic dye Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 150000003716 vitamin K3 derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
Definitions
- compositions which are beneficial for immune health comprise vitamin K2 or a prodrug thereof and vitamin D, which act synergistically together to improve immune health.
- the compositions of the invention can be used as nutraceuticals, and can be used in the fortification of foods or simply as dietary supplements. They may also have utility as pharmaceuticals for the treatment of immune conditions.
- Boosting immune health is desirable because of both the emergence of new diseases and the increasing immuno-resistance of known diseases. Immune health products are relevant in the nutraceutical as well as pharmaceutical fields.
- TNF-alpha is a pleiotropic cytokine and mediates many activities in the body such as modulation of cell recruitment, cell proliferation, cell death and immune regulation.
- TNF-alpha is a pleiotropic cytokine and mediates many activities in the body such as modulation of cell recruitment, cell proliferation, cell death and immune regulation.
- the level of TNF-alpha is elevated, and methods for down regulation of TNF-alpha activity is shown to be beneficial for several conditions like arthritis, Chron’s disease, psoriasis, ulcerative colitis (for example, see Tracey, D., L. Klareskog, E. H. Sasso, J. G. Salfeld and P. P.
- compositions and products of the present invention therefore have highly desirable potential applications in immune health maintenance/improvement.
- the invention provides a composition comprising (I) vitamin K2 or prodrug thereof;
- vitamin D wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is at least 44:1.
- the invention provides a composition comprising
- vitamin D wherein the weight ratio of MK-7 or prodrug thereof to vitamin D is at least
- the invention provides an oral administration dosage form comprising a composition as defined herein.
- the invention provides a composition as defined herein for use in the treatment or prevention of a condition associated with vitamin K deficiencies, such as bone disease, an immune condition, cardiovascular disease, or eye disease, preferably an immune condition.
- a condition associated with vitamin K deficiencies such as bone disease, an immune condition, cardiovascular disease, or eye disease, preferably an immune condition.
- the invention provides a composition as defined herein for use in the treatment or prevention of a condition associated with TNFa dysregulation, such as an immune condition.
- the invention provides a method of preventing or treating bone disease, an immune condition, cardiovascular disease, or eye disease, preferably immune condition, comprising administering to a subject in need thereof an effective amount of a composition as defined herein.
- the invention provides a method of maintaining or improving general immune health, comprising administering to a subject an effective amount of a composition as defined herein.
- the invention provides the use of a composition as defined herein for the manufacture of a medicament for the treatment of bone disease, an immune condition, cardiovascular disease, or eye disease, preferably an immune condition
- the invention provides the use of a composition as defined herein as a nutraceutical product, preferably a nutraceutical product to promote immune health.
- the invention provides the use of a composition as defined herein for maintaining and/or improving the general immune health of a subject.
- This invention relates to vitamin K2-containing compositions and their use in maintaining and/or improving immune health in particular.
- Vitamin K2 or prodrug thereof denotes a group of lipophilic and hydrophobic vitamins that are needed for the post-translational modification of certain proteins, mostly required for blood coagulation. Chemically they are 2-methyl-1 , 4-naphthoquinone derivatives.
- Vitamin K is not a single compound, rather it is a series of related homologues.
- Vitamin K1 is called phylloquinone and has the systematic name all- E-2-methyl-3-(3,7,11 ,15-tetramethylhexadec-2-enyl)naphthalene-1 ,4-dione.
- Vitamin K2 is a mixture of different molecules based on a naphthoquinone structure and varying lengths of isoprenoid chains.
- the compound MK-7 i.e. 7 isoprenyl groups
- Menaquinones have side chains composed of all-E polyprenyl residues; generally they are designated as MK-n, where n specifies the number of isoprenoid repeating units. The minimum value of n is 2.
- vitamin K2 occurs naturally in low concentrations in various fermented food products such as cheese, vitamin K2 can be produced by fermentation of soy beans, or can be produced synthetically.
- compositions of the invention comprise vitamin K2.
- Vitamin K2 is particularly beneficial over vitamin K1 for improving immune health, as it is better absorbed, and has a longer half-life.
- the half-life of vitamin K1 is 1 .5 hours whereas the half-life of vitamin K2 MK-7 is 68 hours.
- the long chain menaquinones associate with LDL particles, and this allows a broader, extrahepatic distribution in the body compared to vitamin K1 .
- Vitamin K2 is a specific subset of vitamin K compounds. Vitamin K1 , for example, has very different physiological data compared to vitamin K2.
- the vitamin K2 (which is preferably MK-7) or prodrug thereof makes up at least 50 wt%, preferably at least 75 wt%, preferably at least 90 wt%, preferably at least 95 wt%, preferably at least 99 wt% of any vitamin K in the composition.
- the composition does not comprise any other vitamin K other than vitamin K2.
- the vitamin K2 in the compositions of the invention is a menaquinone MK-n, where n specifies the number of isoprenoid repeating units, and n is between 2 and 10, preferably between 4 and 8.
- the vitamin K2 is MK-4 or MK-7. More preferably, the vitamin K2 is MK-7.
- the composition of the invention may also comprise a plurality of menaquinone MK-n compounds. The use of MK-7 in particular is beneficial because that is more efficiently absorbed compared to both shorter and longer MK-n (like MK-4 and MK-9).
- the vitamin K2 compounds of the invention may be in cis- or trans-forms, i.e. the polyisoprene chain may have cis- as well as trans- double bonds.
- the polysioprene chain on the MK-7 has all-trans geometry, however.
- the composition may comprise a prodrug of the vitamin K2.
- vitamin K2 can suffer from stability issues with regards to oxygen and light. Racemisation of the double bonds in the isoprenoid chain leads to an inactive vitamin K2 analogue and these double bonds are obviously susceptible to oxidation. Also, the naphthoquinone ring itself is susceptible to oxidation.
- the use of prodrugs may be beneficial, for example, in compositions which require longer shelf-life or are particularly exposed to oxygen and light.
- Useful prodrugs of vitamin K2 can be prepared from diester derivatives, where the ketone functionalities of the naphthoquinone ring are protected.
- the disubstituted vitamin K2 analogues are capable of undergoing hydrolysis and oxidation in the body to release the equivalent menaquinone type structure.
- disubstituted compounds are more stable than the vitamin itself in solution and therefore have a longer shelf life. It is even envisaged that these compounds might also improve the bioavailability of the active component.
- prodrugs are more polar than MK-7 itself. That makes the compounds more easy to formulate and may increase their bioavailability within the body.
- R is preferably -COMe. Both R groups should be the same.
- vitamin K2 in combination with vitamin D, inhibits TNF-a synergistically.
- vitamin K2 Since one of the key ingredients is vitamin K2, it is envisaged that the compositions are not only useful in improving/maintaining immune health, but also in preventing or treating conditions associated with vitamin K2 deficiencies (e.g. bone health). This benefit can also be seen in relation to other organs or biostructures which are affected by or associated with vitamin K2.
- vitamin K2 is relevant for bone health or conditions of the cardiovascular system such as arteriosclerosis.
- the advantage of using vitamin K2 is therefore two-fold. Firstly, it acts synergistically with vitamin D to maintain and/or improve immune health, as can be seen by TNF-alpha inhibition data. Secondly, the administration of vitamin K has benefits in terms of acting on other organs/biostructures which are affected by or associated with vitamin K2.
- the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D is at least 37:1 , preferably at least 38:1 , preferably at least 39:1 , preferably at least 40:1 , preferably at least 41 :1 , preferably at least 42:1 , preferably at least 43:1 , preferably at least 44:1 , preferably at least 45:1 , preferably at least 50:1 , preferably at least 51 :1 , preferably at least 70:1 , preferably at least 71 :1 , preferably at least 72:1 , preferably at least 73:1 , preferably at least 74:1 , preferably at least 75:1 , preferably at least 76:1 , preferably at least 100:1 , preferably at least 200:1 , more preferably at least 250:1 , more preferably at least 270:1 , more preferably at least 300:1 , more preferably
- the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D is at most 65,000:1 , preferably at most 50,000:1 , preferably at most 25,000:1 , more preferably at most 10,000:1 , more preferably at most 9,000:1 , more preferably at most 8,000:1 , more preferably at most 7,000: 1 , more preferably at most 6,000: 1 , more preferably at most 5,000: 1 , more preferably at most 4,500:1 , more preferably at most 4,000:1 , more preferably at most 3,750:1.
- the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D is in the range 37:1 to 50,000:1 , preferably 38:1 to 50,000:1 , preferably 39:1 to 50,000:1 , preferably 40:1 to 50,000:1 , preferably 41 :1 to 50,000:1 , 42:1 to 50,000:1 , preferably 43:1 to 50,000:1 , preferably 44:1 to 50,000:1 , preferably 45:1 to 50,000:1 , preferably 50:1 to 50,000:1 , preferably 75:1 to 50,000:1 , preferably 100:1 to 50,000:1 , more preferably 200:1 to 50,000:1 , more preferably 250:1 to 25,000:1 , more preferably 300:1 to 10,000:1 , more preferably 400:1 to 9,000:1 , more preferably 500:1 to 8,000:1 , more preferably 750:1 to 7,000:
- MK-7 or prodrug thereof) to vitamin D include 37:1 to 50,000:1 , preferably 37:1 to 25,000:1 , preferably 37:1 to 10,000:1 , preferably 37:1 to 5,000:1 , preferably 37:1 to 3,500:1 , preferably 37:1 to 2,000:1 , preferably 37:1 to 1 ,000:1 , preferably 37:1 to 500:1 , preferably 37:1 to 250:1 , preferably 37:1 to 250:1.
- Other suitable ranges include 44:1 to 50,000:1 , preferably 44:1 to 25,000:1 , preferably 44:1 to 10,000:1 , preferably 44:1 to 5,000:1 , preferably 44:1 to 3,500:1 , preferably 44:1 to 2,000:1 , preferably 44:1 to 1 ,000:1 , preferably 44:1 to 500:1 , preferably 44:1 to 250:1 , preferably 44:1 to 100:1 .
- the vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) is present in the composition of the invention in an amount of at least 20 pg, preferably at least 50 pg, preferably at least 80 pg, preferably at least 90 pg.
- the vitamin K2 or prodrug thereof is present in the composition of the invention in an amount of at most 50,000 pg, preferably at most 10,000 pg, preferably at most 2000 pg, preferably at most 1000 pg, preferably at most 900 pg, preferably at most 750 pg, preferably at most 500 pg, preferably at most 300 pg.
- Suitable ranges include amounts of vitamin K2 or prodrug thereof of 20 to 10,000 pg, preferably 20 to 2000 pg, preferably 20 to 1000 pg, preferably 50 to 500 pg, preferably 90-500 pg, more preferably 90 to 300 pg.
- vitamin K2 can also be daily dosages.
- composition of the present invention also comprises vitamin D.
- vitamin D is vitamin D2 or D3, more preferably vitamin D3 (also known as cholecalciferol).
- Vitamin D is known as an immune regulator. It is surprising, however, that the combination of vitamin D with vitamin K2 results in a synergistic inhibition of TNF-alpha.
- the vitamin D is present in the compositions of the invention in an amount of at least 0.1 pg, preferably at least 1 pg, preferably at least 2 pg preferably at least 5 pg, more preferably at least 10 pg.
- the vitamin D is present in the compositions of the invention in an amount of at most 1000 pg, preferably at most 500 pg, preferably at most 250 pg, preferably at most 100 pg, preferably at most 75 pg, preferably at most 50 pg.
- the vitamin D is present in the compositions of the invention in an amount of 0.1 to 500 pg, preferably 1 to 500 pg, preferably 2 to 250 pg, preferably 5 to 100 pg, preferably 5 to 75 pg, preferably 5 to 50 pg.
- vitamin D can also be daily dosages.
- compositions of the present invention show beneficial results at low amounts of vitamin D.
- compositions of the invention are particularly suited for improving immune health. This can be seen through the effect of the compositions on TNF-a inhibition.
- the invention provides a composition as defined herein for use in the treatment or prevention of a condition associated with TNFa dysregulation, such as an immune condition.
- compositions of the invention are (or can be part of) nutraceutical products or pharmaceutical products.
- the compositions are for use as nutraceutical products for maintaining and/or improving immune health.
- the uses/methods described herein are non-therapeutic.
- Vitamin K2 (in particular MK-7) has well documented therapeutic applications and the compositions of the present invention are suitable for all known therapeutic applications of vitamin K2. They can also be used as a food supplement or in any nutraceutical product, e.g. as a vitamin supplement.
- vitamin K2 administration may assist treatment
- cardiovascular health in general such as arteriosclerosis, myocardial infarction, calcification of blood vessels, diabetes, male infertility, conditions associated with inflammation and so on.
- composition can also comprise nutrients selected from osteopontin or salts of magnesium, calcium, phosphorus, magnesium, zinc, iron, copper, manganese, calcium, or combinations thereof, preferably salts of magnesium and/or calcium.
- the composition of the invention is for use in the prevention or treatment of bone disease, cardiovascular disease, or eye disease.
- bone disease is meant any disease relating to the growth, mineralization, microarchitecture, bone organic matrix constituents, density, elasticity and/or strength of the bone, such as osteoporosis.
- a particular cardiovascular disease of interest is arteriosclerosis.
- a particular eye disease of interest is macular degeneration.
- the composition of the invention is for use as a medicament, in particular for use in the prevention or treatment of an immune condition.
- immune condition is typically meant a condition selected from type 1 diabetes, rheumathoid arthritis (RA), psoriasis, psoriatic arthritis, multiple sclerosis (MS), Systemic lupus erythematosus (SLE), inflammatory bowel disease, Addison’s disease, Grave’s disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Pernicious anemia, Celiac disease.
- RA rheumathoid arthritis
- MS multiple sclerosis
- SLE Systemic lupus erythematosus
- Addison’s disease Grave’s disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Pernicious anemia, Celiac disease.
- compositions are equally applicable to any formulations, dosage forms, products etc. comprising the composition of the invention.
- compositions are for administration to a ‘subject’
- said subject is an animal or human subject, preferably human.
- the compounds of the present invention may be utilized alone or in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for which the compositions of the present invention may have utility.
- compositions of the present invention may therefore be formulated as pharmaceutically acceptable compositions or nutraceutically acceptable compositions using known excipients.
- compositions of the invention may also be used in combination therapy with other active agents.
- compositions of the invention may be administered as the bulk substance, it is preferable to present the composition in a pharmaceutical or nutraceutical formulation, for example, wherein the composition is in admixture with an acceptable carrier/excipient.
- the invention provides a pharmaceutical or nutraceutical formulation comprising the composition of the present invention and at least one excipient.
- carrier refers to a diluent, and/or vehicle with which the composition is administered.
- the compositions of the invention may contain one carrier or combinations of more than one carrier.
- Such carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers.
- Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin, 18th Edition.
- compositions may comprise as, in addition to, the carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).
- compositions for use in accordance with the present invention may be in the form of oral (or other mucosally administered) suspensions, powders, capsules or tablets, which may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.
- Oral and enteral administration methods are preferred, preferably oral administration, e.g. in the form of a capsule (preferably a soft gel capsule), tablet, powder, powder for use in a beverage or food, gel, syrup, juice, food, food supplement, beverage, nutraceutical product, pharmaceutical product, veterinary product, a feed or feed supplement, a personal care product, preferably a nutraceutical or pharmaceutical product, preferably a nutraceutical product for oral administration.
- Tablet form and capsule form are particularly preferred administration forms.
- the compositions are not in the form of capsules, e.g. soft-gel capsules.
- composition/formulation requirements there may be different composition/formulation requirements depending on the different delivery systems.
- the composition comprises more than one active component, then those components may be administered by the same or different routes, preferably the same.
- the pharmaceutical or nutraceutical formulations of the present invention can be liquids that are suitable for oral or mucosal administration, for example, drops, syrups, solutions, that are ready for use or are prepared by the dilution of a freeze-dried product but are preferably solid or semisolid as tablets, capsules, granules, powders, pellets or solutions, suspensions, emulsions, or other forms suitable for oral administration.
- composition of the invention can be administered for immediate-, delayed-, modified-, sustained-, pulsed-or controlled-release applications.
- oral compositions are slow, delayed or positioned release (e.g., enteric especially colonic release) tablets or capsules.
- the composition of the invention is microencapsulated, e.g. using techniques described in WO2015/169816.
- Examples of pharmaceutically acceptable or nutraceutically acceptable disintegrants for oral compositions useful in the present invention include, but are not limited to, starch, pre-gelatinized starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, microcrystalline cellulose, alginates, resins, surfactants, effervescent compositions, aqueous aluminium silicates and crosslinked polyvinylpyrrolidone.
- Examples of pharmaceutically acceptable or nutraceutically acceptable binders for oral compositions useful herein include, but are not limited to, acacia; cellulose derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxyethylcellulose; gelatin, glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, pre-gelatinized starch, tragacanth, xanthane resin, alginates, magnesium- aluminum silicate, polyethylene glycol or bentonite.
- acacia cellulose derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxyethylcellulose
- gelatin glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, pre-gelatinized starch, traga
- Examples of pharmaceutically acceptable or nutraceutically acceptable fillers for oral compositions include, but are not limited to, lactose, anhydrolactose, lactose monohydrate, sucrose, dextrose, mannitol, sorbitol, starch, cellulose (particularly microcrystalline cellulose), dihydro- or anhydro- calcium phosphate, calcium carbonate and calcium sulfate.
- compositions of the invention include, but are not limited to, magnesium stearate, talc, polyethylene glycol, polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and colloidal silicon dioxide.
- suitable pharmaceutically acceptable or nutraceutically acceptable odorants for the oral compositions include, but are not limited to, synthetic aromas and natural aromatic oils such as extracts of oils, flowers, fruits (e.g., banana, apple, sour cherry, peach) and combinations thereof, and similar aromas. Their use depends on many factors, the most important being the organoleptic acceptability for the population that will be taking the pharmaceutical compositions.
- suitable pharmaceutically acceptable or nutraceutically acceptable dyes for the oral compositions include, but are not limited to, synthetic and natural dyes such as titanium dioxide, beta-carotene and extracts of grapefruit peel.
- Suitable examples of pharmaceutically acceptable or nutraceutically acceptable sweeteners for the oral compositions include, but are not limited to, aspartame, saccharin, saccharin sodium, sodium cyclamate, xylitol, mannitol, sorbitol, lactose and sucrose.
- Suitable examples of pharmaceutically acceptable buffers include, but are not limited to, citric acid, sodium citrate, sodium bicarbonate, dibasic sodium phosphate, magnesium oxide, calcium carbonate and magnesium hydroxide.
- Suitable examples of pharmaceutically acceptable or nutraceutically acceptable surfactants include, but are not limited to, sodium lauryl sulfate and polysorbates.
- Suitable examples of pharmaceutically acceptable or nutraceutically acceptable preservatives include, but are not limited to, various antibacterial and antifungal agents such as solvents, for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).
- solvents for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).
- Suitable examples of pharmaceutically acceptable or nutraceutically acceptable stabilizers and antioxidants include, but are not limited to, ethylenediaminetetriacetic acid (EDTA), thiourea, tocopherol and butyl hydroxyanisole.
- EDTA ethylenediaminetetriacetic acid
- thiourea thiourea
- tocopherol thiourea
- butyl hydroxyanisole ethylenediaminetetriacetic acid
- compositions of the invention may be taken once a day, twice a day, more often or less often depending on the purpose of administration, preferably once a day.
- a dosage of 1 to 50,000 pg/day is suitable, preferably 1 to 10,000 pg/day, 5 to 5,000 pg/day, preferably 5 to 5,000 pg/day, preferably 10 to 2,000 pg/day, preferably 25 to 1 ,000 pg/day, preferably 50 to 1 ,000 pg/day, preferably 100 to 1 ,000 pg/day, preferably 200 to 1 ,000 pg/day, preferably 240 to 1 ,000 pg/day, based on the combined amount of vitamin K2 and vitamin D.
- Figure 1 shows the inhibition of LPS-induced TNF-a production by macrophages for the cells only, for inventive composition 1 (MIX), for comparative composition 1 (Vit K2 (MK-7)), and for comparative composition 2 (vit D3).
- Figure 2 shows the TNF-a inhibitory effects of inventive composition 1 (‘MIX’) in comparison to the sum of the TNF-a inhibitory effects of components (l)-(ll).
- compositions were investigated for TNF-a inhibition.
- Table 1 Mixes used for TNF-a inhibition studies. In vitro testing on immune health - TNF- a inhibition studies
- TNF-a was selected as a target because of its well-known role in immune health.
- the toxicity of the compositions were tested by metabolic activity.
- Immuno-modulating activity of vitamin K2 (MK-7) and the metabolic active version of vitamin D3 (1a,25-(OH)2D3) was studied by following the cytokine production of THP-1 , macrophages.
- One batch of the THP-1 cell line was used for all the experiments and cells were cultured in a 5% C02 humidified atmosphere at 37°C, in cell culture medium (RPMI, Gibco/Thermo Fisher), supplemented with 10% (v/v) fetal bovine serum, and 1% penicillin-streptomycin (all obtained from Invitrogen, Breda, The Netherlands).
- the human THP-1 cell line was cultured 1x10 5 cells/well in 96-well plates in the presence of 100nM phorbol 12-myristate 13-acetate (PMA, Sigma) and incubated for 48 hours to induce differentiation of the THP-1 monocytes into MO macrophages. Cells were washed and incubated for another 72 hours in culture medium. After this the cells were incubated for one hour with the test components (diluted in DMSO), after which the cells were incubated for another 16 hours with LPS (100 ng/ml, Sigma) in the presence of the test components. Supernatants were collected for analysis of TNF-alpha by ELISA assay (Life Technologies).
- Metabolic activity of the cells was tested after collection of the supernatant using a WST-1 assay. This colorimetric assay assesses the metabolic activity of the cells. This activity can be used as indication for cell proliferation, cell viability and cytotoxicity.
- the WST-1 reagent was added to 50 mI of cell culture medium which was left behind on the cells. OD450 was measured after 4h of incubation of the WST-1 reagent.
- Figure 1 and Table 2 show the effects on TNF-a production by macrophages of inventive composition 1 (mix) and the comparative compositions 1-2 (individual components).
- Figure 1 and Table 2 show the results of the inhibition studies on LPS-induced TNF-a production by macrophages
- Figure 2 and Table 3 show the difference in TNF-a production between the cells only and inventive composition 1 (‘MIX’), and between the cells only and the sum of inhibitory effects of comparative compositions 1 -2 (‘SUM’).
- Table 3 Difference in TNF-a production between the cells only and inventive composition 1 (‘MIX’), and between the cells only and the sum of inhibitory effects of comparative compositions 1-2 (‘SUM’)
Abstract
A composition comprising (I) vitamin K2 or prodrug thereof; (II) vitamin D wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is at least 44:1.
Description
COMPOSITION COMPRISING VITAMIN K, VITAMIN D
Field of the invention
The present invention relates to compositions which are beneficial for immune health. In particular, the compositions of the invention comprise vitamin K2 or a prodrug thereof and vitamin D, which act synergistically together to improve immune health. The compositions of the invention can be used as nutraceuticals, and can be used in the fortification of foods or simply as dietary supplements. They may also have utility as pharmaceuticals for the treatment of immune conditions.
Background of the invention
Boosting immune health is desirable because of both the emergence of new diseases and the increasing immuno-resistance of known diseases. Immune health products are relevant in the nutraceutical as well as pharmaceutical fields.
There are a number of nutraceutical/pharmaceutical products on the market. Improving the efficacy of these compositions is clearly desirable. The present inventors aim to provide compositions which have a clear beneficial effect on immune health. TNF-alpha is a pleiotropic cytokine and mediates many activities in the body such as modulation of cell recruitment, cell proliferation, cell death and immune regulation. At sites of inflammation, the level of TNF-alpha is elevated, and methods for down regulation of TNF-alpha activity is shown to be beneficial for several conditions like arthritis, Chron’s disease, psoriasis, ulcerative colitis (for example, see Tracey, D., L. Klareskog, E. H. Sasso, J. G. Salfeld and P. P. Tak (2008). "Tumor necrosis factor antagonist mechanisms of action: a comprehensive review." Pharmacol Ther 117(21: 244-279).. The present inventors have surprisingly found that vitamin K2 and vitamin D can act synergistically to inhibit TNF-a. The compositions and products of the present invention therefore have highly desirable potential applications in immune health maintenance/improvement.
Summary of the invention
Viewed from a first aspect, the invention provides a composition comprising
(I) vitamin K2 or prodrug thereof;
(II) vitamin D wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is at least 44:1.
Viewed from another aspect, the invention provides a composition comprising
(I) MK-7 or prodrug thereof;
(II) vitamin D wherein the weight ratio of MK-7 or prodrug thereof to vitamin D is at least
37:1.
Viewed from another aspect, the invention provides an oral administration dosage form comprising a composition as defined herein.
Viewed from another aspect, the invention provides a composition as defined herein for use in the treatment or prevention of a condition associated with vitamin K deficiencies, such as bone disease, an immune condition, cardiovascular disease, or eye disease, preferably an immune condition.
Viewed from another aspect, the invention provides a composition as defined herein for use in the treatment or prevention of a condition associated with TNFa dysregulation, such as an immune condition.
Viewed from another aspect, the invention provides a method of preventing or treating bone disease, an immune condition, cardiovascular disease, or eye disease, preferably immune condition, comprising administering to a subject in need thereof an effective amount of a composition as defined herein.
Viewed from another aspect, the invention provides a method of maintaining or improving general immune health, comprising administering to a subject an effective amount of a composition as defined herein.
Viewed from another aspect, the invention provides the use of a composition as defined herein for the manufacture of a medicament for the treatment of bone disease, an immune condition, cardiovascular disease, or eye disease, preferably an immune condition
Viewed from another aspect, the invention provides the use of a composition as defined herein as a nutraceutical product, preferably a nutraceutical product to promote immune health.
Viewed from another aspect, the invention provides the use of a composition as defined herein for maintaining and/or improving the general immune health of a subject.
The features of the aspects and/or embodiments indicated herein are usable individually and in combination in all aspects and embodiments of the invention where technically viable, unless otherwise indicated.
Detailed description of the invention This invention relates to vitamin K2-containing compositions and their use in maintaining and/or improving immune health in particular.
Vitamin K2 or prodrug thereof Vitamin K denotes a group of lipophilic and hydrophobic vitamins that are needed for the post-translational modification of certain proteins, mostly required for blood coagulation. Chemically they are 2-methyl-1 , 4-naphthoquinone derivatives.
Vitamin K is not a single compound, rather it is a series of related homologues. Vitamin K1 is called phylloquinone and has the systematic name all- E-2-methyl-3-(3,7,11 ,15-tetramethylhexadec-2-enyl)naphthalene-1 ,4-dione.
Vitamin K2 is a mixture of different molecules based on a naphthoquinone structure and varying lengths of isoprenoid chains. The compound MK-7 (i.e. 7 isoprenyl groups) is depicted below but other components of the vitamin have different numbers of isoprenoid links. Menaquinones have side chains composed of all-E polyprenyl residues; generally they are designated as MK-n, where n specifies the number of isoprenoid repeating units. The minimum value of n is 2.
Whilst vitamin K2 occurs naturally in low concentrations in various fermented food products such as cheese, vitamin K2 can be produced by fermentation of soy beans, or can be produced synthetically.
The compositions of the invention comprise vitamin K2. Vitamin K2 is particularly beneficial over vitamin K1 for improving immune health, as it is better absorbed, and has a longer half-life. As an example, the half-life of vitamin K1 is 1 .5 hours whereas the half-life of vitamin K2 MK-7 is 68 hours. In addition, the long chain menaquinones associate with LDL particles, and this allows a broader, extrahepatic distribution in the body compared to vitamin K1 . Vitamin K2 is a specific subset of vitamin K compounds. Vitamin K1 , for example, has very different physiological data compared to vitamin K2. In a particular embodiment, the vitamin K2 (which is preferably MK-7) or prodrug thereof makes up at least 50 wt%, preferably at least 75 wt%, preferably at least 90 wt%, preferably at least 95 wt%, preferably at least 99 wt% of any vitamin K in the composition. In a particular embodiment, the composition does not comprise any other vitamin K other than vitamin K2.
Preferably, the vitamin K2 in the compositions of the invention is a menaquinone MK-n, where n specifies the number of isoprenoid repeating units, and n is between 2 and 10, preferably between 4 and 8. Preferably, the vitamin K2 is MK-4 or MK-7. More preferably, the vitamin K2 is MK-7. The composition of the invention may also comprise a plurality of menaquinone MK-n compounds. The use of MK-7 in particular is beneficial because that is more efficiently absorbed compared to both shorter and longer MK-n (like MK-4 and MK-9).
The vitamin K2 compounds of the invention may be in cis- or trans-forms, i.e. the polyisoprene chain may have cis- as well as trans- double bonds.
Preferably, the polysioprene chain on the MK-7 has all-trans geometry, however.
The composition may comprise a prodrug of the vitamin K2. In particular, vitamin K2 can suffer from stability issues with regards to oxygen and light. Racemisation of the double bonds in the isoprenoid chain leads to an inactive vitamin K2 analogue and these double bonds are obviously susceptible to oxidation. Also, the naphthoquinone ring itself is susceptible to oxidation. The use of prodrugs may be beneficial, for example, in compositions which require longer shelf-life or are particularly exposed to oxygen and light.
Useful prodrugs of vitamin K2 can be prepared from diester derivatives, where the ketone functionalities of the naphthoquinone ring are protected. The
disubstituted vitamin K2 analogues are capable of undergoing hydrolysis and oxidation in the body to release the equivalent menaquinone type structure. Moreover, disubstituted compounds are more stable than the vitamin itself in solution and therefore have a longer shelf life. It is even envisaged that these compounds might also improve the bioavailability of the active component.
An advantage of the prodrugs is that they are more polar than MK-7 itself. That makes the compounds more easy to formulate and may increase their bioavailability within the body.
Prodrugs of vitamin K2 are preferably diester analogues of vitamin K2 such as those of formula (I):
wherein each R is COAr, -COC1-6 alkyl group; each Ar is an optionally substituted phenyl, said substituent being a Ci-6 alkyl; and n is 2 to 8 such as 3 to 8, e.g. n=5. R is preferably -COMe. Both R groups should be the same.
As is seen in the data below, vitamin K2, in combination with vitamin D, inhibits TNF-a synergistically.
Since one of the key ingredients is vitamin K2, it is envisaged that the compositions are not only useful in improving/maintaining immune health, but also in preventing or treating conditions associated with vitamin K2 deficiencies (e.g. bone health). This benefit can also be seen in relation to other organs or biostructures which are affected by or associated with vitamin K2. For example, it is known that vitamin K2 is relevant for bone health or conditions of the cardiovascular system such as arteriosclerosis. The advantage of using vitamin K2 is therefore two-fold. Firstly, it acts synergistically with vitamin D to maintain and/or improve immune health, as can be seen by TNF-alpha inhibition data. Secondly, the
administration of vitamin K has benefits in terms of acting on other organs/biostructures which are affected by or associated with vitamin K2.
The ranges, amounts etc. disclosed herein or in the claims can refer to vitamin K2 or MK-7 (or prodrugs thereof).
In a particular embodiment, the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D is at least 37:1 , preferably at least 38:1 , preferably at least 39:1 , preferably at least 40:1 , preferably at least 41 :1 , preferably at least 42:1 , preferably at least 43:1 , preferably at least 44:1 , preferably at least 45:1 , preferably at least 50:1 , preferably at least 51 :1 , preferably at least 70:1 , preferably at least 71 :1 , preferably at least 72:1 , preferably at least 73:1 , preferably at least 74:1 , preferably at least 75:1 , preferably at least 76:1 , preferably at least 100:1 , preferably at least 200:1 , more preferably at least 250:1 , more preferably at least 270:1 , more preferably at least 300:1 , more preferably at least 400:1 , more preferably at least 500:1 , more preferably at least 750:1 , more preferably at least 1000: 1 , more preferably at least 1500: 1 , more preferably at least 2000: 1 , more preferably at least 2500:1 , more preferably at least 3000:1.
In a particular embodiment, the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D is at most 65,000:1 , preferably at most 50,000:1 , preferably at most 25,000:1 , more preferably at most 10,000:1 , more preferably at most 9,000:1 , more preferably at most 8,000:1 , more preferably at most 7,000: 1 , more preferably at most 6,000: 1 , more preferably at most 5,000: 1 , more preferably at most 4,500:1 , more preferably at most 4,000:1 , more preferably at most 3,750:1.
In a particular embodiment, the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D is in the range 37:1 to 50,000:1 , preferably 38:1 to 50,000:1 , preferably 39:1 to 50,000:1 , preferably 40:1 to 50,000:1 , preferably 41 :1 to 50,000:1 , 42:1 to 50,000:1 , preferably 43:1 to 50,000:1 , preferably 44:1 to 50,000:1 , preferably 45:1 to 50,000:1 , preferably 50:1 to 50,000:1 , preferably 75:1 to 50,000:1 , preferably 100:1 to 50,000:1 , more preferably 200:1 to 50,000:1 , more preferably 250:1 to 25,000:1 , more preferably 300:1 to 10,000:1 , more preferably 400:1 to 9,000:1 , more preferably 500:1 to 8,000:1 , more preferably 750:1 to 7,000:1 , more preferably 1 ,000:1 to 6,000:1 , more preferably 1 ,500:1 to 5,500:1 , more preferably 2,000:1 to 5,000:1 , more preferably 2,500:1 to 4,000:1 , more preferably 3,000:1 to 4,000:1 , more preferably 3,000:1 to 3,750:1
Other suitable ranges for the weight ratio of vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) to vitamin D include 37:1 to 50,000:1 , preferably 37:1 to 25,000:1 , preferably 37:1 to 10,000:1 , preferably 37:1 to 5,000:1 , preferably 37:1 to 3,500:1 , preferably 37:1 to 2,000:1 , preferably 37:1 to 1 ,000:1 , preferably 37:1 to 500:1 , preferably 37:1 to 250:1 , preferably 37:1 to 250:1. Other suitable ranges include 44:1 to 50,000:1 , preferably 44:1 to 25,000:1 , preferably 44:1 to 10,000:1 , preferably 44:1 to 5,000:1 , preferably 44:1 to 3,500:1 , preferably 44:1 to 2,000:1 , preferably 44:1 to 1 ,000:1 , preferably 44:1 to 500:1 , preferably 44:1 to 250:1 , preferably 44:1 to 100:1 .
Typically, the vitamin K2 or prodrug thereof (e.g. MK-7 or prodrug thereof) is present in the composition of the invention in an amount of at least 20 pg, preferably at least 50 pg, preferably at least 80 pg, preferably at least 90 pg. In another embodiment, the vitamin K2 or prodrug thereof is present in the composition of the invention in an amount of at most 50,000 pg, preferably at most 10,000 pg, preferably at most 2000 pg, preferably at most 1000 pg, preferably at most 900 pg, preferably at most 750 pg, preferably at most 500 pg, preferably at most 300 pg. Suitable ranges include amounts of vitamin K2 or prodrug thereof of 20 to 10,000 pg, preferably 20 to 2000 pg, preferably 20 to 1000 pg, preferably 50 to 500 pg, preferably 90-500 pg, more preferably 90 to 300 pg.
The amounts given herein for vitamin K2 can also be daily dosages.
Vitamin D
The composition of the present invention also comprises vitamin D. Preferably the vitamin D is vitamin D2 or D3, more preferably vitamin D3 (also known as cholecalciferol).
Vitamin D is known as an immune regulator. It is surprising, however, that the combination of vitamin D with vitamin K2 results in a synergistic inhibition of TNF-alpha.
Typically, the vitamin D is present in the compositions of the invention in an amount of at least 0.1 pg, preferably at least 1 pg, preferably at least 2 pg preferably at least 5 pg, more preferably at least 10 pg. Typically, the vitamin D is present in the compositions of the invention in an amount of at most 1000 pg, preferably at most 500 pg, preferably at most 250 pg, preferably at most 100 pg, preferably at most 75 pg, preferably at most 50 pg. Typically, the vitamin D is
present in the compositions of the invention in an amount of 0.1 to 500 pg, preferably 1 to 500 pg, preferably 2 to 250 pg, preferably 5 to 100 pg, preferably 5 to 75 pg, preferably 5 to 50 pg.
The amounts given herein for vitamin D can also be daily dosages.
Unexpectedly, the compositions of the present invention show beneficial results at low amounts of vitamin D.
Compositions and applications
The compositions of the invention are particularly suited for improving immune health. This can be seen through the effect of the compositions on TNF-a inhibition. In a particular aspect, the invention provides a composition as defined herein for use in the treatment or prevention of a condition associated with TNFa dysregulation, such as an immune condition.
The compositions of the invention are (or can be part of) nutraceutical products or pharmaceutical products. Preferably, the compositions are for use as nutraceutical products for maintaining and/or improving immune health. In a particular embodiment, the uses/methods described herein are non-therapeutic.
Vitamin K2 (in particular MK-7) has well documented therapeutic applications and the compositions of the present invention are suitable for all known therapeutic applications of vitamin K2. They can also be used as a food supplement or in any nutraceutical product, e.g. as a vitamin supplement.
Conditions in which vitamin K2 administration may assist treatment include osteoporosis and bone related disorders, cardiovascular health in general such as arteriosclerosis, myocardial infarction, calcification of blood vessels, diabetes, male infertility, conditions associated with inflammation and so on.
The composition can also comprise nutrients selected from osteopontin or salts of magnesium, calcium, phosphorus, magnesium, zinc, iron, copper, manganese, calcium, or combinations thereof, preferably salts of magnesium and/or calcium.
In a further particular embodiment, the composition of the invention is for use in the prevention or treatment of bone disease, cardiovascular disease, or eye disease. By bone disease is meant any disease relating to the growth, mineralization, microarchitecture, bone organic matrix constituents, density, elasticity and/or strength of the bone, such as osteoporosis. A particular
cardiovascular disease of interest is arteriosclerosis. A particular eye disease of interest is macular degeneration.
In a particular embodiment, the composition of the invention is for use as a medicament, in particular for use in the prevention or treatment of an immune condition. By immune condition is typically meant a condition selected from type 1 diabetes, rheumathoid arthritis (RA), psoriasis, psoriatic arthritis, multiple sclerosis (MS), Systemic lupus erythematosus (SLE), inflammatory bowel disease, Addison’s disease, Grave’s disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, Myasthenia gravis, Autoimmune vasculitis, Pernicious anemia, Celiac disease.
Any of the uses or methods described or claimed herein for the compositions are equally applicable to any formulations, dosage forms, products etc. comprising the composition of the invention.
Where it is described herein that the composition are for administration to a ‘subject’, said subject is an animal or human subject, preferably human.
The compounds of the present invention may be utilized alone or in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for which the compositions of the present invention may have utility.
The compositions of the present invention may therefore be formulated as pharmaceutically acceptable compositions or nutraceutically acceptable compositions using known excipients. The compositions of the invention may also be used in combination therapy with other active agents.
While it is possible that the compositions of the invention may be administered as the bulk substance, it is preferable to present the composition in a pharmaceutical or nutraceutical formulation, for example, wherein the composition is in admixture with an acceptable carrier/excipient. In a particular embodiment, therefore, the invention provides a pharmaceutical or nutraceutical formulation comprising the composition of the present invention and at least one excipient.
The term "carrier" or "excipient" refers to a diluent, and/or vehicle with which the composition is administered. The compositions of the invention may contain one carrier or combinations of more than one carrier. Such carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, 18th Edition. The choice of pharmaceutical carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, in addition to, the carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).
It will be appreciated that compositions for use in accordance with the present invention may be in the form of oral (or other mucosally administered) suspensions, powders, capsules or tablets, which may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients. Oral and enteral administration methods are preferred, preferably oral administration, e.g. in the form of a capsule (preferably a soft gel capsule), tablet, powder, powder for use in a beverage or food, gel, syrup, juice, food, food supplement, beverage, nutraceutical product, pharmaceutical product, veterinary product, a feed or feed supplement, a personal care product, preferably a nutraceutical or pharmaceutical product, preferably a nutraceutical product for oral administration. Tablet form and capsule form are particularly preferred administration forms. In a particular embodiment, the compositions are not in the form of capsules, e.g. soft-gel capsules.
There may be different composition/formulation requirements depending on the different delivery systems. As the composition comprises more than one active component, then those components may be administered by the same or different routes, preferably the same.
The pharmaceutical or nutraceutical formulations of the present invention can be liquids that are suitable for oral or mucosal administration, for example, drops, syrups, solutions, that are ready for use or are prepared by the dilution of a freeze-dried product but are preferably solid or semisolid as tablets, capsules, granules, powders, pellets or solutions, suspensions, emulsions, or other forms suitable for oral administration.
The composition of the invention can be administered for immediate-, delayed-, modified-, sustained-, pulsed-or controlled-release applications.
In one aspect, oral compositions are slow, delayed or positioned release (e.g., enteric especially colonic release) tablets or capsules.
In one embodiment the composition of the invention is microencapsulated, e.g. using techniques described in WO2015/169816.
As mentioned above, oral administration is preferred. Examples of pharmaceutically acceptable or nutraceutically acceptable disintegrants for oral compositions useful in the present invention include, but are not limited to, starch, pre-gelatinized starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, microcrystalline cellulose, alginates, resins, surfactants, effervescent compositions, aqueous aluminium silicates and crosslinked polyvinylpyrrolidone.
Examples of pharmaceutically acceptable or nutraceutically acceptable binders for oral compositions useful herein include, but are not limited to, acacia; cellulose derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxyethylcellulose; gelatin, glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, pre-gelatinized starch, tragacanth, xanthane resin, alginates, magnesium- aluminum silicate, polyethylene glycol or bentonite.
Examples of pharmaceutically acceptable or nutraceutically acceptable fillers for oral compositions include, but are not limited to, lactose, anhydrolactose, lactose monohydrate, sucrose, dextrose, mannitol, sorbitol, starch, cellulose (particularly microcrystalline cellulose), dihydro- or anhydro- calcium phosphate, calcium carbonate and calcium sulfate.
Examples of pharmaceutically acceptable or nutraceutically acceptable lubricants useful in the compositions of the invention include, but are not limited to, magnesium stearate, talc, polyethylene glycol, polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and colloidal silicon dioxide.
Examples of suitable pharmaceutically acceptable or nutraceutically acceptable odorants for the oral compositions include, but are not limited to, synthetic aromas and natural aromatic oils such as extracts of oils, flowers, fruits (e.g., banana, apple, sour cherry, peach) and combinations thereof, and similar aromas. Their use depends on many factors, the most important being the organoleptic acceptability for the population that will be taking the pharmaceutical compositions.
Examples of suitable pharmaceutically acceptable or nutraceutically acceptable dyes for the oral compositions include, but are not limited to, synthetic
and natural dyes such as titanium dioxide, beta-carotene and extracts of grapefruit peel.
Suitable examples of pharmaceutically acceptable or nutraceutically acceptable sweeteners for the oral compositions include, but are not limited to, aspartame, saccharin, saccharin sodium, sodium cyclamate, xylitol, mannitol, sorbitol, lactose and sucrose. Suitable examples of pharmaceutically acceptable buffers include, but are not limited to, citric acid, sodium citrate, sodium bicarbonate, dibasic sodium phosphate, magnesium oxide, calcium carbonate and magnesium hydroxide.
Suitable examples of pharmaceutically acceptable or nutraceutically acceptable surfactants include, but are not limited to, sodium lauryl sulfate and polysorbates.
Suitable examples of pharmaceutically acceptable or nutraceutically acceptable preservatives include, but are not limited to, various antibacterial and antifungal agents such as solvents, for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).
Suitable examples of pharmaceutically acceptable or nutraceutically acceptable stabilizers and antioxidants include, but are not limited to, ethylenediaminetetriacetic acid (EDTA), thiourea, tocopherol and butyl hydroxyanisole.
The compositions of the invention may be taken once a day, twice a day, more often or less often depending on the purpose of administration, preferably once a day.
The dose and the administration frequency will depend on the use in question, e.g. whether for clinical use or via a supplement. A dosage of 1 to 50,000 pg/day is suitable, preferably 1 to 10,000 pg/day, 5 to 5,000 pg/day, preferably 5 to 5,000 pg/day, preferably 10 to 2,000 pg/day, preferably 25 to 1 ,000 pg/day, preferably 50 to 1 ,000 pg/day, preferably 100 to 1 ,000 pg/day, preferably 200 to 1 ,000 pg/day, preferably 240 to 1 ,000 pg/day, based on the combined amount of vitamin K2 and vitamin D.
Brief description of Figures
Figure 1 shows the inhibition of LPS-induced TNF-a production by macrophages for the cells only, for inventive composition 1 (MIX), for comparative composition 1 (Vit K2 (MK-7)), and for comparative composition 2 (vit D3). Figure 2 shows the TNF-a inhibitory effects of inventive composition 1 (‘MIX’) in comparison to the sum of the TNF-a inhibitory effects of components (l)-(ll). MIX: The delta of the effect (effect size) of the mix was calculated (=cells only - mix). SUM: The sum of the effect of the single components in the mix was calculated ((=cells only - comparative composition 1) + (cells only - comparative composition 2).
Examples
Table 1 : Mixes used for TNF-a inhibition studies. In vitro testing on immune health - TNF- a inhibition studies
TNF-a was selected as a target because of its well-known role in immune health. The toxicity of the compositions were tested by metabolic activity. Immuno-modulating activity of vitamin K2 (MK-7) and the metabolic active version of vitamin D3 (1a,25-(OH)2D3) was studied by following the cytokine production of THP-1 , macrophages. One batch of the THP-1 cell line was used for all the experiments and cells were cultured in a 5% C02 humidified atmosphere at 37°C, in cell culture medium (RPMI, Gibco/Thermo Fisher), supplemented with 10% (v/v) fetal bovine serum, and 1% penicillin-streptomycin (all obtained from Invitrogen, Breda, The Netherlands).
The human THP-1 cell line was cultured 1x105 cells/well in 96-well plates in the presence of 100nM phorbol 12-myristate 13-acetate (PMA, Sigma) and incubated for 48 hours to induce differentiation of the THP-1 monocytes into MO macrophages. Cells were washed and incubated for another 72 hours in culture medium. After this the cells were incubated for one hour with the test components (diluted in DMSO), after which the cells were incubated for another 16 hours with LPS (100 ng/ml, Sigma) in the presence of the test components. Supernatants were collected for analysis of TNF-alpha by ELISA assay (Life Technologies).
Metabolic activity of the cells was tested after collection of the supernatant using a WST-1 assay. This colorimetric assay assesses the metabolic activity of the cells. This activity can be used as indication for cell proliferation, cell viability and cytotoxicity. Upon collection of the supernatants for the TNF-alpha detection, the WST-1 reagent was added to 50 mI of cell culture medium which was left behind on the cells. OD450 was measured after 4h of incubation of the WST-1 reagent.
Results The results are shown in Figures 1 , 2 and Tables 2, 3. Figure 1 and Table 2 show the effects on TNF-a production by macrophages of inventive composition 1 (mix) and the comparative compositions 1-2 (individual components). Figure 1 and Table 2 show the results of the inhibition studies on LPS-induced TNF-a production by macrophages, and Figure 2 and Table 3 show the difference in TNF-a production between the cells only and inventive composition 1 (‘MIX’), and between the cells only and the sum of inhibitory effects of comparative compositions 1 -2 (‘SUM’).
It can be seen that there is a synergistic effect for the combination of vitamin K2 and vitamin D since the inhibitory effect by the combination of these components is greater than the sum of the inhibitory effects of each component individually. Having more vitamin K2 than vitamin D is particularly beneficial.
Table 3: Difference in TNF-a production between the cells only and inventive composition 1 (‘MIX’), and between the cells only and the sum of inhibitory effects of comparative compositions 1-2 (‘SUM’)
Example 2
The following composition was prepared: - MK-7: 220-500 meg
- Vit D3: 5-10 meg
Claims
1. A composition comprising
(I) vitamin K2 or prodrug thereof; (II) vitamin D wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is at least 44:1.
2. A composition comprising (I) MK-7 or prodrug thereof;
(II) vitamin D wherein the weight ratio of MK-7 or prodrug thereof to vitamin D is at least
37:1.
3. A composition as claimed in any preceding claim, wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is at least 51 :1 , preferably at least 75:1 , preferably at least 100:1 , preferably at least 200:1 , more preferably at least 250:1 , more preferably at least 270:1 , more preferably at least 300:1 , more preferably at least 400:1 , more preferably at least 500:1 , more preferably at least 750:1 , more preferably at least 1000: 1 , more preferably at least 1500: 1 , more preferably at least 2000: 1 , more preferably at least 2500: 1 , more preferably at least 3000: 1 .
4. A composition as claimed in any preceding claim, wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is at most 65,000:1 , preferably at most 50,000:1 , preferably at most 25,000:1 , more preferably at most 10,000:1 , more preferably at most 9,000:1 , more preferably at most 8,000:1 , more preferably at most 7,000: 1 , more preferably at most 6,000: 1 , more preferably at most 5,000: 1 , more preferably at most 4,500:1 , more preferably at most 4,000:1 , more preferably at most 3,750:1.
5. A composition as claimed in any preceding claim, wherein the weight ratio of vitamin K2 or prodrug thereof to vitamin D is in the range 37:1 to 50,000:1 , preferably 44:1 to 50,000:1 , preferably 75:1 to 50,000:1 , preferably 100:1 to 50,000:1 , more preferably 200:1 to 50,000:1 , more preferably 250:1 to 25,000:1 , more preferably 300:1 to 10,000:1 , more preferably 400:1 to 9,000:1 , more
preferably 500:1 to 8,000:1 , more preferably 750:1 to 7,000:1 , more preferably 1 ,000:1 to 6,000:1 , more preferably 1 ,500:1 to 5,500:1 , more preferably 2,000:1 to 5,000:1 , more preferably 2,500:1 to 4,000:1 , more preferably 3,000:1 to 4,000:1 , more preferably 3,000:1 to 3,750:1 , or in the range 37:1 to 25,000:1 , preferably 37:1 to 10,000:1 , preferably 37:1 to 5,000:1 , preferably 37:1 to 3,500:1 , preferably 37:1 to 2,000:1 , preferably 37:1 to 1 ,000:1 , preferably 37:1 to 500:1 , preferably 37:1 to 250:1 , preferably 37:1 to 250:1 , or in the range 44:1 to 25,000:1 , preferably 44:1 to 10,000:1 , preferably 44:1 to 5,000:1 , preferably 44:1 to 3,500:1 , preferably 44:1 to 2,000:1 , preferably 44:1 to
I ,000:1 , preferably 44:1 to 500:1 , preferably 44:1 to 250:1 , preferably 44:1 to 100:1.
6. A composition as claimed in any preceding claim, wherein said vitamin K2 is MK-7.
7. A composition as claimed in any preceding claim, wherein said vitamin D is vitamin D3.
8. A composition as claimed in any preceding claim, comprising vitamin K2 in an amount of at least 20 pg, preferably at least 50 pg, more preferably at least preferably at least 80 pg, preferably at least 90 pg.
9. A composition as claimed in any preceding claim, comprising vitamin K2 in an amount of at most 50,000 pg, preferably at most 10,000 pg, preferably at most 2000 pg, preferably at most 1000 pg, preferably at most 900 pg, preferably at most 750 pg, preferably at most 500 pg, preferably at most 300 pg.
10. A composition as claimed in any preceding claim, comprising vitamin D in an amount of at least 0.1 pg, preferably at least 1 pg, preferably at least 2 pg preferably at least 5 pg, more preferably at least 10 pg
I I . A composition as claimed in any preceding claim, comprising vitamin D in an amount of at most 1000 pg, preferably at most 500 pg, preferably at most 250 pg, preferably at most 100 pg, preferably at most 75 pg, preferably at most 50 pg.
12. A composition as claimed in any preceding claim, wherein the vitamin K2 and vitamin D act synergistically in inhibiting TNF-alpha.
13. An oral administration dosage form comprising a composition as claimed in 1 to 12.
14. An oral administration dosage form as claimed in 13, in the form of a capsule (preferably a soft gel capsule), tablet, powder, powder for use in a beverage or food, gel, syrup, juice, food, food supplement, beverage, veterinary product, a feed or feed supplement, a personal care product.
15. A composition as claimed in claims 1-12 for use in the treatment or prevention of an immune condition.
16. A composition as claimed in claims 1-12 for use in the treatment or prevention of a condition associated with TNFa dysregulation, such as an immune condition.
17. A method of preventing or treating an immune condition, comprising administering to a subject in need thereof an effective amount of a composition as claimed in 1-12.
18. A method of maintaining or improving general immune health, comprising administering to a subject an effective amount of a composition as claimed in 1-12.
19. Use of a composition as claimed in 1-12 for the manufacture of a medicament for the treatment of an immune condition.
20. The use of a composition as claimed in claims 1-12 as a nutraceutical product, preferably a nutraceutical product to promote immune health.
21 . The use of a composition as claimed in claims 1-12 for maintaining and/or improving the general immune health of a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2109362.0 | 2021-06-29 | ||
GB2109362.0A GB2608393A (en) | 2021-06-29 | 2021-06-29 | Vitamin K2 compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023275149A1 true WO2023275149A1 (en) | 2023-01-05 |
Family
ID=77179526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/067908 WO2023275149A1 (en) | 2021-06-29 | 2022-06-29 | Composition comprising vitamin k, vitamin d |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2608393A (en) |
WO (1) | WO2023275149A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842722B2 (en) * | 2003-12-19 | 2010-11-30 | Alcon, Inc. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
US20130095204A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Nutritional phytonutrient compositions |
WO2014028621A1 (en) * | 2012-08-14 | 2014-02-20 | Abbott Laboratories | Methods and compositions useful for improving bone and joint health |
WO2015169816A1 (en) | 2014-05-05 | 2015-11-12 | Basf Se | Formulation of fat-soluble vitamin |
ITPD20140287A1 (en) * | 2014-10-30 | 2016-04-30 | Fusaro Maria | K-PHARMA |
US20180055802A1 (en) * | 2016-08-31 | 2018-03-01 | Nse Products, Inc. | Nutritional compositions and associated methods |
CN108125246A (en) * | 2018-01-24 | 2018-06-08 | 安徽顺和生物科技有限公司 | A kind of pregnant woman and wet nurse's nutrient supplement food formula |
CN110604308A (en) * | 2018-06-14 | 2019-12-24 | 深圳芙莱特营养与健康有限公司 | A nutritional composition with analgesic effect |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103142640A (en) * | 2013-04-01 | 2013-06-12 | 李拖平 | Health care product containing vitamin K2 and having functions of preventing and treating brittle-bone disease |
CN108936687A (en) * | 2018-08-08 | 2018-12-07 | 深圳极醇健康产业股份有限公司 | A kind of soft capsule and preparation method thereof of replenishing vitamins KD calcium |
CN113018264A (en) * | 2021-02-05 | 2021-06-25 | 澳汀斯(广州)生物医药科技有限公司 | Vitamin-encapsulated nano liposome preparation and preparation method thereof |
-
2021
- 2021-06-29 GB GB2109362.0A patent/GB2608393A/en active Pending
-
2022
- 2022-06-29 WO PCT/EP2022/067908 patent/WO2023275149A1/en active Search and Examination
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842722B2 (en) * | 2003-12-19 | 2010-11-30 | Alcon, Inc. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
US20130095204A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Nutritional phytonutrient compositions |
WO2014028621A1 (en) * | 2012-08-14 | 2014-02-20 | Abbott Laboratories | Methods and compositions useful for improving bone and joint health |
WO2015169816A1 (en) | 2014-05-05 | 2015-11-12 | Basf Se | Formulation of fat-soluble vitamin |
ITPD20140287A1 (en) * | 2014-10-30 | 2016-04-30 | Fusaro Maria | K-PHARMA |
US20180055802A1 (en) * | 2016-08-31 | 2018-03-01 | Nse Products, Inc. | Nutritional compositions and associated methods |
CN108125246A (en) * | 2018-01-24 | 2018-06-08 | 安徽顺和生物科技有限公司 | A kind of pregnant woman and wet nurse's nutrient supplement food formula |
CN110604308A (en) * | 2018-06-14 | 2019-12-24 | 深圳芙莱特营养与健康有限公司 | A nutritional composition with analgesic effect |
Non-Patent Citations (6)
Title |
---|
E.W. MARTIN: "Remington's Pharmaceutical Sciences" |
HUNT DAVID W ET AL: "Effect of menaquinone-4, vitamin D and n-3 fats on ovariectomized rat bone loss", FASEB JOURNAL, vol. 21, no. 5, April 2007 (2007-04-01), & EXPERIMENTAL BIOLOGY 2007 ANNUAL MEETING; WASHINGTON, DC, USA; APRIL 28 -MAY 02, 2007, pages A357, XP009539910, ISSN: 0892-6638 * |
IIJIMA HIDEKI ET AL: "The importance of vitamins D and K for the bone health and immune function in inflammatory bowel disease.", CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE NOV 2012, vol. 15, no. 6, November 2012 (2012-11-01), pages 635 - 640, XP009536072, ISSN: 1473-6519 * |
LEE K H ET AL: "Preventive effects of co-treatment with fucoidan and lutein on the development of inflammatory bowel disease in DSS mouse model", NATURAL PRODUCT SCIENCES 2011 KOREAN SOCIETY OF PHARMACOGNOSY KOR, vol. 17, no. 3, 2011, pages 234 - 238, XP009536073, ISSN: 1226-3907 * |
SCHWANKE RAQUEL CRISTINA ET AL: "EPA- and DHA-derived resolvins' actions in inflammatory bowel disease", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 785, 29 August 2015 (2015-08-29), pages 156 - 164, XP029669766, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2015.08.050 * |
TRACEY, D.L. KLARESKOGE. H. SASSOJ. G. SALFELDP. P. TAK: "Tumor necrosis factor antagonist mechanisms of action: a comprehensive review", PHARMACOL THER, vol. 117, no. 2, 2008, pages 244 - 279, XP022432143, DOI: 10.1016/j.pharmthera.2007.10.001 |
Also Published As
Publication number | Publication date |
---|---|
GB202109362D0 (en) | 2021-08-11 |
GB2608393A (en) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10245239B2 (en) | Astaxanthin anti-inflammatory synergistic combinations | |
US7786175B2 (en) | Anti-atherosclerosis composition containing carotenoids and method for inhibiting LDL oxidation | |
CA2761717A1 (en) | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | |
CN114982971A (en) | Fat-soluble vitamin preparation | |
CN111920878B (en) | Anti-aging composition and application thereof | |
US20140378543A1 (en) | Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances | |
EP2981256B1 (en) | Anti-inflammatory synergistic combinations comprising omega-3 fatty acid, tomato lycopene, lutein and carnosic acid | |
AU2005253914B2 (en) | Use of alpha-ketoglutarate and related compounds for lowering plasma lipids | |
JP7100882B2 (en) | Oral composition | |
CA2847543C (en) | Annatto extract compositions, including geranyl geraniols and methods of use | |
US20050154066A1 (en) | Antiaging composition | |
Rasheed et al. | Toxicity and tissue distribution of methylsulfonylmethane following oral gavage in broilers | |
CA2550186A1 (en) | Antiaging composition | |
AU2002226652A1 (en) | An anti-atherosclerosis composition containing carotenoids and method for inhibiting LDL oxidation | |
EP3001912A1 (en) | Pharmaceutical or nutraceutical composition | |
WO2023275149A1 (en) | Composition comprising vitamin k, vitamin d | |
KR20190058346A (en) | Composition comprising chp (cyclo-his pro) for preventing, improving or treating of bone loss related disease | |
WO2023275183A1 (en) | Composition comprising vitamin k, vitamin d, xanthophyll and epa and/or dha | |
JP2010105946A (en) | Muscle protein enhancer and drug or food containing the same | |
US20210346315A1 (en) | Composition for inhibition or treatment of brain tumors or symptoms attributable thereto | |
WO2019016988A1 (en) | Composition | |
US6867234B2 (en) | Fat composition for oral or enternal administration and hexacosanoic acid depressant | |
EP4140474A1 (en) | Nutraceutical for the reduction of osteoarthritic pain and inflammation | |
CN114748486A (en) | A food containing vitamin K2Pharmaceutical composition for improving cardiovascular calcification and preparation method and application thereof | |
KR20130102307A (en) | Composition for improving heart and liver function and functional food comprising thererof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22741195 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |